Maintenance Therapy with Opium Tincture for Injecting Drug Users; Implications for Prevention from Viral Infections

authors:

avatar Zahra Alam Mehrjerdi 1 , * , avatar Mehran Zarghami 2

Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, IR Iran
Department of Psychiatry and Psychiatry and Behavioral Sciences Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran
Hepatitis Monthly: Vol.13, issue 4; e8334
published online: April 16, 2013
article type: Letter
received: September 27, 2012
accepted: October 8, 2012
DOI: https://doi.org/10.5812/hepatmon.8334

how to cite: Alam Mehrjerdi Z, Zarghami M. Maintenance Therapy with Opium Tincture for Injecting Drug Users; Implications for Prevention from Viral Infections. Hepat Mon. 2013;13(4):e8334. https://doi.org/10.5812/hepatmon.8334.

References

  • 1.

    Alavi SM, Behdad F. Seroprevalence study of hepatitis C and Hepatitis B virus among hospitalized intravenous drug users in Ahvaz, Iran (2002-2006). Hepat Mon. 2010;10(2):101-4. [PubMed ID: 22312381].

  • 2.

    Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi EM, Baghestani AR, Jafari S. Factors Correlated With Hepatitis C and B Virus Infections Among Injecting Drug Users in Tehran, IR Iran. Hepat Mon. 2012;12(1):23-31. [PubMed ID: 22451840]. https://doi.org/10.5812/kowsar.1735143X.806.

  • 3.

    Kassaian N, Adibi P, Kafashaian A, Yaran M, Nokhodian Z, Shoaei P, et al. Hepatitis C Virus and Associated Risk Factors among Prison Inmates with History of Drug Injection in Isfahan, Iran. Int J Prev Med. 2012;3(Suppl 1):S156-61. [PubMed ID: 22826759].

  • 4.

    Kheirandish P, Seyedalinaghi SA, Hosseini M, Jahani MR, Shirzad H, Foroughi M, et al. Prevalence and correlates of HIV infection among male injection drug users in detention in Tehran, Iran. J Acquir Immune Defic Syndr. 2010;53(2):273-5. [PubMed ID: 20104123]. https://doi.org/10.1097/QAI.0b013e3181be6dde.

  • 5.

    Hosseini M, SeyedAlinaghi S, Kheirandish P, Esmaeli Javid G, Shirzad H, Karami N, et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med. 2010;13(4):318-23. [PubMed ID: 20597566].

  • 6.

    Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007;18(5):359-63. [PubMed ID: 17854723]. https://doi.org/10.1016/j.drugpo.2007.02.007.

  • 7.

    Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence--a comparison between injection and noninjection drug users in New York City. J Urban Health. 2004;81(1):20-4. [PubMed ID: 15047780]. https://doi.org/10.1093/jurban/jth084.

  • 8.

    Nataparan C. 2000. Methadone maintenance and harm reduction in northern Thailand. Available from: http://www.drugtext.org/Opiates-heroin-methadone/methadone-maintenance-and-harm-reduction-in-northern-thailand.html.

  • 9.

    Chandrasena R. Management of opium dependence in a general hospital psychiatry unit. Br J Addict. 1980;75(2):163-7. [PubMed ID: 6930293].

  • 10.

    Somogyi AA, Larsen M, Abadi RM, Jittiwutikarn J, Ali R, White JM. Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 2008;66(5):640-7. [PubMed ID: 19032172]. https://doi.org/10.1111/j.1365-2125.2008.03277.x.

  • 11.

    Auriacombe M, Grabot D, Daulouede JP, Vergnolle JP, O'Brien C, Tignol J. A naturalistic follow-up study of French-speaking opiate-maintained heroin-addicted patients: effect on biopsychosocial status. J Subst Abuse Treat. 1994;11(6):565-8. [PubMed ID: 7884840].

  • 12.

    Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iranian Med. 2002;5(3):184-90.

  • 13.

    2011. United nations office on drug and crime. World drug report. Available from: http://www.unodc.org/unodc/en/data-and-analysis/WDR-2011.html.

  • 14.

    Nissaramanesh B, Trace M, Roberts M. The rise of harm reduction in the Islamic Republic of Iran. Beckley Foundation Drug Policy Programme, Briefing Paper. 2005;8.

  • 15.

    Razzaghi E, Nassirimanesh B, Afshar P, Ohiri K, Claeson M, Power R. HIV/AIDS harm reduction in Iran. Lancet. 2006;368(9534):434-5. [PubMed ID: 16890814]. https://doi.org/10.1016/S0140-6736(06)69132-0.

  • 16.

    Zamani S, Vazirian M, Nassirimanesh B, Razzaghi EM, Ono-Kihara M, Mortazavi Ravari S, et al. Needle and syringe sharing practices among injecting drug users in Tehran: a comparison of two neighborhoods, one with and one without a needle and syringe program. AIDS Behav. 2010;14(4):885-90. [PubMed ID: 18483849]. https://doi.org/10.1007/s10461-008-9404-2.

  • 17.

    2011. Analysis of the world situation. Available from: http://www.incb.org/documents/Publications/AnnualReports/AR2011/AR_2011_E_Chapter_III.pdf.

  • 18.

    Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103(9):1484-92. [PubMed ID: 18636999]. https://doi.org/10.1111/j.1360-0443.2008.02249.x.

  • 19.

    Razani N, Mohraz M, Kheirandish P, Malekinejad M, Malekafzali H, Mokri A, et al. HIV risk behavior among injection drug users in Tehran, Iran. Addiction. 2007;102(9):1472-82. [PubMed ID: 17645427]. https://doi.org/10.1111/j.1360-0443.2007.01914.x.

  • 20.

    Zarghami M. Is methadone substitution the best treatment of choice for opioid dependence? Iran J Psychiatry Behav Sci. 2008;2(2):1-4.